Globus Medical Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Globus Medical stock.
View analyst ratings for Globus Medical or view top-rated stocks.

Wall Street analysts have given Globus Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Globus Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Globus Medical saw a decline in short interest during the month of August. As of August 13th, there was short interest totaling 1,160,000 shares, a decline of 17.1% from the July 29th total of 1,400,000 shares. Based on an average daily volume of 393,900 shares, the short-interest ratio is presently 2.9 days. Approximately 1.5% of the shares of the stock are sold short.
View Globus Medical's Short Interest.

Globus Medical is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Globus Medical.

Globus Medical, Inc. (NYSE:GMED) posted its earnings results on Wednesday, August, 4th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.12. The medical device company had revenue of $251.02 million for the quarter, compared to the consensus estimate of $225.50 million. Globus Medical had a net margin of 19.83% and a trailing twelve-month return on equity of 14.10%. The company's revenue for the quarter was up 68.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.07 EPS.
View Globus Medical's earnings history.

Globus Medical's stock was trading at $38.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GMED stock has increased by 108.2% and is now trading at $79.22.
View which stocks have been most impacted by COVID-19.

Globus Medical updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of $2.000-$2.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.890. The company issued revenue guidance of $950 million-$950 million, compared to the consensus revenue estimate of $926.78 million.

11 brokerages have issued 12-month price objectives for Globus Medical's shares. Their forecasts range from $56.00 to $96.00. On average, they expect Globus Medical's stock price to reach $82.18 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts' price targets for Globus Medical or view top-rated stocks among Wall Street analysts.

47 employees have rated Globus Medical CEO David Demski on Glassdoor.com. David Demski has an approval rating of 61% among Globus Medical's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Globus Medical include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of GMED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), The Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.32%), Vanguard Group Inc. (7.23%), State Street Corp (2.11%), Champlain Investment Partners LLC (1.51%), AXA S.A. (1.47%) and Kayne Anderson Rudnick Investment Management LLC (1.26%). Company insiders that own Globus Medical stock include Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends for Globus Medical.

GMED stock was sold by a variety of institutional investors in the last quarter, including Van Berkom & Associates Inc., Nuance Investments LLC, BlackRock Inc., Balyasny Asset Management LLC, Invesco Ltd., Banque Pictet & Cie SA, Citigroup Inc., and Geode Capital Management LLC. Company insiders that have sold Globus Medical company stock in the last year include Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, Keith W Pfeil, and Kelly Huller.
View insider buying and selling activity for Globus Medical or view top insider-selling stocks.

GMED stock was purchased by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Integral Health Asset Management LLC, State Street Corp, Vanguard Group Inc., FMR LLC, Point72 Asset Management L.P., Marathon Asset Management LLP, and Goldman Sachs Group Inc..
View insider buying and selling activity for Globus Medical or or view top insider-buying stocks.

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMED stock can currently be purchased for approximately $79.22.

Globus Medical has a market capitalization of $7.99 billion and generates $789.04 million in revenue each year. The medical device company earns $102.29 million in net income (profit) each year or $1.44 on an earnings per share basis.

Globus Medical employs 2,200 workers across the globe.

The official website for Globus Medical is www.globusmedical.com.

Globus Medical is headquartered at 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403.

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at (610) 930-1800 or via email at [email protected].